My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

NCT02091141 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

673

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Solid Tumors
Biliary Cancer
Salivary Cancer
Bladder Cancer

Interventions

DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Erlotinib
DRUG: Vemurafenib
DRUG: Cobimetinib
DRUG: Vismodegib
DRUG: Alectinib
DRUG: Atezolizumab

Sponsor

Genentech, Inc.